RBC Capital resumed coverage of Privia Health (PRVA) with an Outperform rating and $31 price target Privia is seen as a leading play in physician enablement, a high-growth area at the intersection of technology and healthcare utilization, the analyst tells investors in a research note. Growth is expected to continue as Privia expands its physician network and fee-based collections, leveraging its payor-agnostic model to outpace a market focused on “margin over growth” while value-based care adoption matures through 2026-2027, the firm adds.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Jefferies says CMS new LEAD model ‘clear positive’ for Astrana, Agilon, Privia
- Privia Health Finalizes Acquisition of ACO Business
- Privia Health price target raised to $33 from $32 at JPMorgan
- BMO Capital Highlights Privia Health Group’s Strong Growth Potential and Differentiated Risk Management in Value-Based Care
- Privia Health initiated with an Outperform at BMO Capital